A Second Dose of Measles Vaccine (MV) in the Second Year of Life

Boosting the Beneficial Non-specific Effects of Live Attenuated Vaccines: A Randomized Controlled Trial (RCT) of a Second Dose of Measles Vaccine (MV) in the Second Year of Life

NCT02943681•Bandim Health Project

View on ClinicalTrials.gov

Summary

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

Eligibility

Age

1 - 2 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Children need to have received the third dose of inactivated vaccines (Penta, PCV13 and IPV) before measles vaccination.

Exclusion Criteria

•Having severe malformations that impairs their health
•Having received a second dose of measles vaccine
•Severely ill (requiring hospitalization) upon clinical examination

Locations (1)

Bandim Health Project, Apartado 861

Bissau, Guinea-Bissau

Key Dates

Start Date

October 1, 2016

Primary Completion Date

May 1, 2020

Completion Date

May 1, 2021

Last Updated

January 19, 2024

Enrollment

3,812

ACTUAL participants

Conditions

Child MortalityChild Morbidity

Interventions

Measles vaccine

BIOLOGICAL

Infant Mortality Reduction by the Mass Administration of Azithromycin

NCT04716712

Child Mortality

View study

COMPLETEDNA

Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

NCT04617626

Child MortalityAzithromycin

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions